Synapse - Howard Scher

Results (200)

Evaluating 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA)

Meeting Abstract

Feldman, J. L.; Fox, J. J.; Autio, K. A.; Gavane, S. C.; Heller, G.; Schoder, H.; Humm, J.; Martinez, D. F.; Slovin, S. F.; Scher, H. I.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

Journal Article

Danila, D. C.; Anand, A.; Schultz, N.; Heller, G.; Wan, M.; Sung, C. C.; Dai, C.; Khanin, R.; Fleisher, M.; Lilja, H.; more...
European Urology (2014)

Fulltext@MSK | Save

Bone metastases in castration-resistant prostate cancer: Associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival

Journal Article

Vargas, H. A.; Wassberg, C.; Fox, J. J.; Wibmer, A.; Goldman, D. A.; Kuk, D.; Gonen, M.; Larson, S. M.; Morris, M. J.; Scher, H. I.; more...
Radiology (2014)

Fulltext@MSK | Save

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Risk assessment for severe hypocalcemia requiring hospitalization with denosumab

Meeting Abstract

Autio, K. A.; Farooki, A.; Glezerman, I.; Chan, A.; Barr, H. C.; Seyboth, B. M.; Schneider, C. W.; Heller, G.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer

Meeting Abstract

Subudhi, S. K.; Heller, G.; Danila, D. C.; Anand, A.; Lacuna, K. P.; Samoila, A.; Fleisher, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Anand, A.; Danila, D. C.; Heller, G.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Heller, G.; Molina, A.; Attard, G.; McCormack, R.; Riisnaes, R.; Kheoh, T.; Fleisher, M.; Buyse, M.; de Bono, J. S.
European Journal of Cancer (2013)

Fulltext@MSK | Save

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer

Journal Article

Rathkopf, D. E.; Morris, M. J.; Fox, J. J.; Danila, D. C.; Slovin, S. F.; Hager, J. H.; Rix, P. J.; Chow-Maneval, E.; Chen, I.; Gonen, M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer

Journal Article

Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
Cancer (2013)

Fulltext@MSK | Save